Science & Technology
Recombinant E-NTPDase for shock
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41GM151882-01
Award Ceiling
$300K
Award Floor
$300K
Close Date
Aug 31, 2024
Total Funding
$300K
Expected Awards
1
Posted Date
Sep 21, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R41GM151882-01
Description
STTR Phase Phase I award: "Recombinant E-NTPDase for shock" awarded to Purine Pharmaceuticals Inc. in Gillette, New Jersey. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $299,999. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.